Last updated: February 14, 2026
Overview
NDC 75834-0137 represents a specialized pharmaceutical product, specifically a biologic, approved for the treatment of multiple sclerosis (MS). Its patent and market exclusivity are nearing expiration, prompting an analysis of current market dynamics and future pricing trends.
Market Size and Competitive Landscape
- Market Size: The global MS therapeutic market was valued at approximately $21 billion in 2022. The US accounts for about 45%-50%, corresponding to roughly $10-$11 billion.
- Key Competitors: Several biologics and biosimilars compete in this space, including:
- Tecfidera (dimethyl fumarate)
- Aubagio (teriflunomide)
- Gilenya (fingolimod)
- The biosimilar segment is emerging, with FDA approvals for several products.
- Market Share: NDC 75834-0137 currently holds a 12% share within the biologic space for MS, with annual sales around $2.5 billion. Sales have plateaued due to patent expiry expectations and increasing biosimilar entry.
Pricing Landscape
- Average Wholesale Price (AWP): The current AWP for the drug is approximately $35,000 per year per patient, based on recent market data.
- Reimbursement Rates: Commercial insurances reimburse within a range of 80-85% of AWP. Medicare and Medicaid reimbursement varies but is often lower, affecting net pricing.
- Pricing Trends Over Time: The drug’s price increased steadily from $30,000 to $35,000 over the last five years, driven by inflation and manufacturing costs. The approach of patent expiration in 2024 is influencing pricing strategies.
Patent and Regulatory Status
- Patent Expiry: Patent protection expires in mid-2024, opening the market to biosimilar competition.
- Patent Challenges: Several biosimilar applications are pending approval, with FDA review expected in 2023. Patent challenges may delay biosimilar entry or result in settlement agreements.
- Market Exclusivity: The product benefits from orphan drug designation, extending exclusivity rights until 2024.
Price Projections (2023–2027)
| Year |
Estimated Price per Patient |
Assumptions |
| 2023 |
$35,000 |
Current market rate; increased biosimilar competition expected |
| 2024 |
$32,000 |
Competing biosimilar introductions; price erosion begins |
| 2025 |
$28,000 |
Increased biosimilar market share; discounts of up to 20% |
| 2026 |
$25,000 |
Further biosimilar uptake; possible price stabilization |
| 2027 |
$23,000 |
Market saturation; price stabilization below original levels |
Drivers of Price Erosion
- Biosimilar competition expected to capture 40%-60% market share within two years of launch.
- Payer negotiations favoring lower prices driven by cost-containment strategies.
- Potential legal settlements delaying biosimilar entry or limiting pricing flexibility.
Revenue Impact and Market Entry Strategies
- Pre-Patent Expiry: Revenue sustained through exclusivity; profits driven by high list prices.
- Post-Patent Expiry: Revenue declines as biosimilars capture market share; competitive pricing pressures reduce margins.
- Strategies: Firms should consider lifecycle management including label expansion, patient support programs, and negotiating favorable reimbursement terms to extend market dominance.
Regulatory Landscape and Policy Impact
- Biosimilar Approval Pathways: The FDA approves biosimilars based on biosimilarity and lack of clinically meaningful differences.
- Pricing Policies: CMS initiatives may aim to cap reimbursement or incentivize biosimilar adoption, influencing net revenues.
- Legislative Changes: Proposed legislation in 2023 encourages biosimilar market entry, which could accelerate price erosion.
Summary
NDC 75834-0137 faces imminent biosimilar competition, leading to a decline in average selling prices projected from $35,000 in 2023 to roughly $23,000 by 2027. Revenue and market share are expected to decline correspondingly, emphasizing the importance of early lifecycle management strategies.
Key Takeaways
- The product's patent protection ends in 2024, with biosimilar competition likely to reduce prices significantly.
- Market share is expected to decrease from approximately 12% to less than 5% within two years of biosimilar entry.
- Pricing will trend downward, from $35,000 to near $23,000 per patient annually by 2027.
- The primary growth driver pre-exclusivity expiration is patent-driven revenue.
- Policy developments in 2023 could accelerate biosimilar adoption and further impact pricing.
FAQs
-
What factors influence biosimilar market entry timing?
Approval timelines, patent litigation, manufacturing capacity, and payer negotiations are primary factors determining biosimilar availability.
-
How does reimbursement policy affect pricing?
Payers prefer lower-cost alternatives, leading to discounts and negotiated rates that compress net revenue.
-
What role do legislative changes play?
Legislation promoting biosimilar competition and reimbursement reforms can accelerate price erosion.
-
What strategies can extend product lifecycle?
Developing new formulations, expanding indications, and enhancing patient support can delay declines.
-
How accurate are these projections?
While based on current data and trends, actual market developments may vary due to regulatory or competitive shifts.
References
[1] IMS Health, "MS Market Analysis," 2022.
[2] FDA, "Biosimilar Approval Pathway," 2023.
[3] IQVIA, "Biologic Market Trends," 2023.
[4] CMS, "Reimbursement Policies for Biologics," 2023.
[5] MarketWatch, "MS Drug Market Forecast," 2023.
